Project: Preparing a multi-purpose therapeutic cancer vaccine platform.

PRIMECURE aims at development of a disruptive technology platform to create and validate off-the-shelf therapeutic cancer vaccines for any type of cancer. The underlying cell line has already been used to generate an AML vaccine, showing great clinical potential in phase I/IIa trials. Now, the cell line and a humanised mouse model will form the basis for building a robust platform to create and in vivo validate highly potent cancer vaccines. Proof of concept will be gathered for ovarian cancer.

Acronym	PRIMECURE (Reference Number: 9704)
Duration	01/10/2015 - 01/10/2018
Project Topic	Biological Sciences / Technologies
Network	Eurostars 2
Call	Eurostars Cut-Off 3

Project partner

Number	Name	Role	Country
21373	TransCure bioServices SAS	Partner	France
21374	DCPrime BV	Coordinator	Netherlands